Supporting this hypothesis, studies have shown that activation of NKT cells can lead to improved outcomes in mice and patients receiving ICT, mainly manifested by the increase of IL-2 (Interleukin 2) and IL-12 (Interleukin 12) by NKT cells upon CD1d stimulation by αGC in APCs, reinvigorating exhausted CD8 T cells in synergism with anti-PD1 therapies in tumor-bearing mice and patients with cancer (55). The gene discussed is CD1D; the disease is neoplasm.